Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation
- 12 January 2004
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 6 (2) , 147-154
- https://doi.org/10.1002/jgm.479
Abstract
Background: Human gene therapy vectors based on primate lentiviruses harbour in contrast to oncoretroviruses the risk of vector mobilization by human immunodeficiency viruses (HIV). Infection of cells transduced with a lentiviral vector by HIV could lead to packaging of the lentiviral vector RNA into HIV particles and transfer of the vector.Methods: A new approach based on primer complementation was developed to reduce the risk of vector mobilization. The primer binding site (PBS) of an SIV‐based vector was mutated abolishing tRNA primer binding and thus blocking reverse transcription. This block was efficiently by‐passed during vector production by providing an artificial tRNA matching the mutated PBS with titers reaching 106 infectious units/ml.Results: Primer‐complemented SIV vectors were mobilized from transduced cells by HIV‐1 >150‐fold less efficiently than vectors with wild‐type PBS. Mobilization of the primer‐complemented SIV vector by SIV was inhibited to a lesser extent indicating reduced efficacy of the primer complementation approach for preventing mobilization of lentiviral vectors by homologous virus. The analysis of the PBS of the vector DNA in target cells transduced with vectors containing mutated PBS in the absence of a matched tRNA suggests that formation of heterozygous particles followed by priming on the helper RNA and strand switch during reverse transcription can lead to mobilization of the primer‐complemented vector by SIV, but not HIV‐1. Although self‐inactivating vectors were more efficient in preventing vector mobilization by HIV‐1 than primer‐complemented vectors, mobilization remained undectable only if both approaches were combined.Conclusions: The primer complementation approach should further reduce the risk of mobilization of self‐inactivating SIV‐based vectors by HIV‐1 and thus increase their safety. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- Comparison of Three Retroviral Vector Systems for Transduction of Nonobese Diabetic/Severe Combined Immunodeficiency Mice Repopulating Human CD34+Cord Blood CellsHuman Gene Therapy, 2003
- Transfer of Primer Binding Site-Mutated Simian Immunodeficiency Virus Vectors by Genetically Engineered Artificial and Hybrid tRNA-Like PrimersJournal of Virology, 2001
- Identification of Critical Elements in the tRNA Acceptor Stem and TΨC Loop Necessary for Human Immunodeficiency Virus Type 1 InfectivityJournal of Virology, 2001
- Generation of a Stable Cell Line Producing High-Titer Self-Inactivating Lentiviral VectorsMolecular Therapy, 2001
- Rev-Independent Expression of Syntheticgag-polGenes of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus: Implications for the Safety of Lentiviral VectorsHuman Gene Therapy, 2000
- Development of a Self-Inactivating, Minimal Lentivirus Vector Based on Simian Immunodeficiency VirusHuman Gene Therapy, 2000
- Stable gene transfer to the nervous system using a non-primate lentiviral vectorGene Therapy, 1999
- Human Immunodeficiency Virus Type 2 Lentivirus Vectors for Gene Transfer: Expression and Potential for Helper Virus-Free PackagingHuman Gene Therapy, 1998
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- HIV-1 Reverse Transcription A Termination Step at the Center of the GenomeJournal of Molecular Biology, 1994